These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 34968173)

  • 21. SARS-CoV-2 vaccines, where do we stand?
    Fischer A
    C R Biol; 2021 Jun; 344(1):43-55. PubMed ID: 34213848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel.
    Swift MD; Breeher LE; Tande AJ; Tommaso CP; Hainy CM; Chu H; Murad MH; Berbari EF; Virk A
    Clin Infect Dis; 2021 Sep; 73(6):e1376-e1379. PubMed ID: 33900384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. COVID-19 and mRNA Vaccines-First Large Test for a New Approach.
    Abbasi J
    JAMA; 2020 Sep; 324(12):1125-1127. PubMed ID: 32880613
    [No Abstract]   [Full Text] [Related]  

  • 24. Impact of mRNA vaccines in curtailing SARS-CoV-2 infection and disability leave utilisation among healthcare workers during the COVID-19 pandemic: cross-sectional analysis from a tertiary healthcare system in the Greater Houston metropolitan area.
    Vahidy FS; Pan AP; Hagan K; Bako AT; Sostman HD; Schwartz RL; Phillips R; Boom ML
    BMJ Open; 2021 Oct; 11(10):e054332. PubMed ID: 34642201
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Messenger RNA vaccines and neutralizing anti-severe acute respiratory syndrome coronavirus 2 antibodies in patients with immunodeficiency.
    Mungmunpuntipantip R; Wiwanitkit V
    Ann Allergy Asthma Immunol; 2021 Dec; 127(6):703. PubMed ID: 34823756
    [No Abstract]   [Full Text] [Related]  

  • 26. Cutaneous reactions due to Pfizer's BNT162b2 mRNA and Moderna's mRNA-1273 vaccines.
    Oulee A; Salem S; Yahia R; Yang K; Garcia D; Holmes A; Furukawa B
    J Eur Acad Dermatol Venereol; 2022 May; 36(5):e332-e334. PubMed ID: 35028998
    [No Abstract]   [Full Text] [Related]  

  • 27. SARS-CoV-2 vaccine candidates in rapid development.
    Li L; Guo P; Zhang X; Yu Z; Zhang W; Sun H
    Hum Vaccin Immunother; 2021 Mar; 17(3):644-653. PubMed ID: 33121319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RNA vaccines: A transformational advance.
    Brown BD; Fauci AS; Belkaid Y; Merad M
    Immunity; 2023 Dec; 56(12):2665-2669. PubMed ID: 38091944
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of BNT162b2 (Pfizer-BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients.
    Kaiser RA; Haller MC; Apfalter P; Kerschner H; Cejka D
    Kidney Int; 2021 Sep; 100(3):697-698. PubMed ID: 34270945
    [No Abstract]   [Full Text] [Related]  

  • 30. Autoimmune Hemolytic Anemia After mRNA COVID Vaccine.
    Fatima Z; Reece BRA; Moore JS; Means RT
    J Investig Med High Impact Case Rep; 2022; 10():23247096211073258. PubMed ID: 35045762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. mRNA Vaccines: Possible Tools to Combat SARS-CoV-2.
    Yi C; Yi Y; Li J
    Virol Sin; 2020 Jun; 35(3):259-262. PubMed ID: 32524253
    [No Abstract]   [Full Text] [Related]  

  • 32. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
    Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
    Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The forerunners and successful partnerships behind the BioNTech mRNA vaccine.
    Aygün I; Barciszewski J
    J Appl Genet; 2024 Feb; 65(1):47-55. PubMed ID: 37861886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Messenger RNA vaccines for cancer immunotherapy: progress promotes promise.
    Huff AL; Jaffee EM; Zaidi N
    J Clin Invest; 2022 Mar; 132(6):. PubMed ID: 35289317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. From mRNA sensing to vaccines.
    Fauci AS; Merad M; Swaminathan S; Hur S; Topol E; Fitzgerald K; Reis e Sousa C; Corbett KS; Bauer S
    Immunity; 2021 Dec; 54(12):2676-2680. PubMed ID: 34739870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interferon Beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects.
    Maniscalco GT; Manzo V; Ferrara AL; Perrella A; Di Battista M; Salvatore S; Graziano D; Viola A; Amato G; Moreggia O; Di Giulio Cesare D; Barbato S; Servillo G; Longo K; Di Giovanni M; Scarpati B; Muggianu SM; Longo G; Russo G; Andreone V; De Rosa V
    Mult Scler Relat Disord; 2022 Feb; 58():103455. PubMed ID: 34929455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
    Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL
    Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Definite Acute Myocarditis After Coronavirus Disease 2019 mRNA Vaccination.
    Maeda M; Isawa T; Tada N
    Circ J; 2022 Mar; 86(4):724. PubMed ID: 34866122
    [No Abstract]   [Full Text] [Related]  

  • 39. Spotlight on Vaccines: Pandemic May Open Gateway to Improve Vaccination Rates in Texas.
    Price S
    Tex Med; 2021 Mar; 117(3):20-25. PubMed ID: 34855954
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
    Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
    Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.